Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01940172 · ClinicalTrials.gov registry record · Phase 1
Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer
A Phase 1 study, sponsored by TetraLogic Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT01940172: Completed Phase 1 study, sponsored by TetraLogic Pharmaceuticals.
NCT01940172 is a Phase 1 study that has completed, run by TetraLogic Pharmaceuticals. The registered enrollment target is 27 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01940172, a Phase 1 study, has completed, sponsored by TetraLogic Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
This is a dose escalation study in female subjects with relapsed ovarian cancer (including epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer). Approximately 30 to 40 subjects will be administered a combination of conatumumab and birinapant. In the initial dose-escalation stage of the study, adult female subjects will receive conatumumab in combination with increasing doses of birinapant in dose-escalation cohorts to determine the MTD of birinapant when administered with a fixed dose of conatumumab. In safety expansion stage, adult female subjects will receive conatumumab in combination with birinapant at the MTD of the combination.
Interventions
- DRUG Birinapant
- DRUG Conatumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2013-11 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01940172
The ClinicalTrials.gov registry entry for NCT01940172 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TetraLogic Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Birinapant is the first listed.
NCT01940172 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01940172 about?
NCT01940172 is a clinical study titled "Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer". This is a dose escalation study in female subjects with relapsed ovarian cancer (including epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer). Approximately 30 to 40 subjects will be administered a combination of conatumumab and birinapant. In the initial dose-escalatio...
What is the current status of trial NCT01940172?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2013-11. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01940172?
The interventions under investigation include: Birinapant (DRUG), Conatumumab (DRUG).
Who is sponsoring clinical trial NCT01940172?
This trial is sponsored by TetraLogic Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.